Skip to main content

How can we help you?

  • Deal or case news
  • 26-02-2021

NautaDutilh assisted InflaRx N.V. with its underwritten public offering of ordinary shares and warrants with a gross proceeds for InflaRx of USD 75 million. The shares are being sold at a public offering price of USD 5.00 per share. For each share purchased, an investor will also receive a warrant to purchase a common share at an exercise price of USD 5.80. The warrants are exercisable immediately and have a term of up to one year.

InflaRx is a Nasdaq listed clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx is a client of NautaDutilh since 2017. 


Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.